CliffBio
small molecule

CANASA

MESALAMINE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameCANASA
Active ingredientMESALAMINE
Strength500MG
Dosage formSUPPOSITORY
RouteRECTAL
ModalitySmall molecule
FDA approvalJanuary 2001
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CANASA patent cliff — loss of exclusivity — | CliffBio